Cargando…
Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts
SIMPLE SUMMARY: Regions of low oxygen status (hypoxia) are a characteristic feature of solid tumors. This hypoxia is a major cause of resistance to treatment, especially radiation therapy, and it can increase the likelihood of metastatic spread. Being able to accurately identify tumor hypoxia will a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198481/ https://www.ncbi.nlm.nih.gov/pubmed/34073301 http://dx.doi.org/10.3390/cancers13112602 |
_version_ | 1783707149240631296 |
---|---|
author | Elming, Pernille B. Wittenborn, Thomas R. Busk, Morten Sørensen, Brita S. Thomsen, Mathilde Borg Houlberg Strandgaard, Trine Dyrskjøt, Lars Nielsen, Steffen Horsman, Michael R. |
author_facet | Elming, Pernille B. Wittenborn, Thomas R. Busk, Morten Sørensen, Brita S. Thomsen, Mathilde Borg Houlberg Strandgaard, Trine Dyrskjøt, Lars Nielsen, Steffen Horsman, Michael R. |
author_sort | Elming, Pernille B. |
collection | PubMed |
description | SIMPLE SUMMARY: Regions of low oxygen status (hypoxia) are a characteristic feature of solid tumors. This hypoxia is a major cause of resistance to treatment, especially radiation therapy, and it can increase the likelihood of metastatic spread. Being able to accurately identify tumor hypoxia will allow us to predict a patient’s response to therapy and find alternative approaches to improve outcome. We have refined a dissection method that involves autoradiography and laser-guided microdissection of hypoxic areas in tumors. Using this approach, we were able to test the feasibility of applying a 15-gene signature that was previously developed for head and neck cancer patients to identify hypoxia in pre-clinical models of prostate cancer. Our results demonstrated the potential of this method to identify hypoxia in this tumor type and suggest its applicability for use in patients with prostate cancer. ABSTRACT: Background: This pre-clinical study was designed to refine a dissection method for validating the use of a 15-gene hypoxia classifier, which was previously established for head and neck squamous cell carcinoma (HNSCC) patients, to identify hypoxia in prostate cancer. Methods: PC3 and DU-145 adenocarcinoma cells, in vitro, were gassed with various oxygen concentrations (0–21%) for 24 h, followed by real-time PCR. Xenografts were established in vivo, and the mice were injected with the hypoxic markers [18F]-FAZA and pimonidazole. Subsequently, tumors were excised, frozen, cryo-sectioned, and analyzed using autoradiography ([18F]-FAZA) and immunohistochemistry (pimonidazole); the autoradiograms used as templates for laser capture microdissection of hypoxic and non-hypoxic areas, which were lysed, and real-time PCR was performed. Results: In vitro, all 15 genes were increasingly up-regulated as oxygen concentrations decreased. With the xenografts, all 15 genes were up-regulated in the hypoxic compared to non-hypoxic areas for both cell lines, although this effect was greater in the DU-145. Conclusions: We have developed a combined autoradiographic/laser-guided microdissection method with broad applicability. Using this approach on fresh frozen tumor material, thereby minimizing the degree of RNA degradation, we showed that the 15-gene hypoxia gene classifier developed in HNSCC may be applicable for adenocarcinomas such as prostate cancer. |
format | Online Article Text |
id | pubmed-8198481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81984812021-06-14 Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts Elming, Pernille B. Wittenborn, Thomas R. Busk, Morten Sørensen, Brita S. Thomsen, Mathilde Borg Houlberg Strandgaard, Trine Dyrskjøt, Lars Nielsen, Steffen Horsman, Michael R. Cancers (Basel) Article SIMPLE SUMMARY: Regions of low oxygen status (hypoxia) are a characteristic feature of solid tumors. This hypoxia is a major cause of resistance to treatment, especially radiation therapy, and it can increase the likelihood of metastatic spread. Being able to accurately identify tumor hypoxia will allow us to predict a patient’s response to therapy and find alternative approaches to improve outcome. We have refined a dissection method that involves autoradiography and laser-guided microdissection of hypoxic areas in tumors. Using this approach, we were able to test the feasibility of applying a 15-gene signature that was previously developed for head and neck cancer patients to identify hypoxia in pre-clinical models of prostate cancer. Our results demonstrated the potential of this method to identify hypoxia in this tumor type and suggest its applicability for use in patients with prostate cancer. ABSTRACT: Background: This pre-clinical study was designed to refine a dissection method for validating the use of a 15-gene hypoxia classifier, which was previously established for head and neck squamous cell carcinoma (HNSCC) patients, to identify hypoxia in prostate cancer. Methods: PC3 and DU-145 adenocarcinoma cells, in vitro, were gassed with various oxygen concentrations (0–21%) for 24 h, followed by real-time PCR. Xenografts were established in vivo, and the mice were injected with the hypoxic markers [18F]-FAZA and pimonidazole. Subsequently, tumors were excised, frozen, cryo-sectioned, and analyzed using autoradiography ([18F]-FAZA) and immunohistochemistry (pimonidazole); the autoradiograms used as templates for laser capture microdissection of hypoxic and non-hypoxic areas, which were lysed, and real-time PCR was performed. Results: In vitro, all 15 genes were increasingly up-regulated as oxygen concentrations decreased. With the xenografts, all 15 genes were up-regulated in the hypoxic compared to non-hypoxic areas for both cell lines, although this effect was greater in the DU-145. Conclusions: We have developed a combined autoradiographic/laser-guided microdissection method with broad applicability. Using this approach on fresh frozen tumor material, thereby minimizing the degree of RNA degradation, we showed that the 15-gene hypoxia gene classifier developed in HNSCC may be applicable for adenocarcinomas such as prostate cancer. MDPI 2021-05-26 /pmc/articles/PMC8198481/ /pubmed/34073301 http://dx.doi.org/10.3390/cancers13112602 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Elming, Pernille B. Wittenborn, Thomas R. Busk, Morten Sørensen, Brita S. Thomsen, Mathilde Borg Houlberg Strandgaard, Trine Dyrskjøt, Lars Nielsen, Steffen Horsman, Michael R. Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts |
title | Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts |
title_full | Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts |
title_fullStr | Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts |
title_full_unstemmed | Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts |
title_short | Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts |
title_sort | refinement of an established procedure and its application for identification of hypoxia in prostate cancer xenografts |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198481/ https://www.ncbi.nlm.nih.gov/pubmed/34073301 http://dx.doi.org/10.3390/cancers13112602 |
work_keys_str_mv | AT elmingpernilleb refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT wittenbornthomasr refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT buskmorten refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT sørensenbritas refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT thomsenmathildeborghoulberg refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT strandgaardtrine refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT dyrskjøtlars refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT nielsensteffen refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts AT horsmanmichaelr refinementofanestablishedprocedureanditsapplicationforidentificationofhypoxiainprostatecancerxenografts |